ANI Pharma (ANIP) Misses Q3 EPS by 20c, Revenues Miss; Offers FY19 EPS/Revenue Guidance Below Consensus

November 6, 2019 8:32 AM

ANI Pharma (NASDAQ: ANIP) reported Q3 EPS of $1.23, $0.20 worse than the analyst estimate of $1.43. Revenue for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found